vs

Side-by-side financial comparison of WEIS MARKETS INC (WMK) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

WEIS MARKETS INC is the larger business by last-quarter revenue ($1.3B vs $805.0M, roughly 1.6× West Pharmaceutical Services). West Pharmaceutical Services runs the higher net margin — 16.4% vs 2.5%, a 13.9% gap on every dollar of revenue. On growth, West Pharmaceutical Services posted the faster year-over-year revenue change (7.5% vs 5.0%). West Pharmaceutical Services produced more free cash flow last quarter ($175.0M vs $36.4M). Over the past eight quarters, West Pharmaceutical Services's revenue compounded faster (7.6% CAGR vs 4.7%).

Weis Markets, Inc., doing business as Weis and stylized as weis, is an American food retailer headquartered in Sunbury, Pennsylvania. It currently operates 200 stores with over 23,000 employees in Pennsylvania, Maryland, New York, New Jersey, West Virginia, Virginia, and Delaware.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

WMK vs WST — Head-to-Head

Bigger by revenue
WMK
WMK
1.6× larger
WMK
$1.3B
$805.0M
WST
Growing faster (revenue YoY)
WST
WST
+2.5% gap
WST
7.5%
5.0%
WMK
Higher net margin
WST
WST
13.9% more per $
WST
16.4%
2.5%
WMK
More free cash flow
WST
WST
$138.6M more FCF
WST
$175.0M
$36.4M
WMK
Faster 2-yr revenue CAGR
WST
WST
Annualised
WST
7.6%
4.7%
WMK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
WMK
WMK
WST
WST
Revenue
$1.3B
$805.0M
Net Profit
$32.0M
$132.1M
Gross Margin
25.3%
37.8%
Operating Margin
3.2%
19.5%
Net Margin
2.5%
16.4%
Revenue YoY
5.0%
7.5%
Net Profit YoY
-5.1%
1.5%
EPS (diluted)
$1.27
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
WMK
WMK
WST
WST
Q4 25
$1.3B
$805.0M
Q3 25
$1.2B
$804.6M
Q2 25
$1.2B
$766.5M
Q1 25
$1.2B
$698.0M
Q4 24
$1.2B
$748.8M
Q3 24
$1.2B
$746.9M
Q2 24
$1.2B
$702.1M
Q1 24
$1.2B
$695.4M
Net Profit
WMK
WMK
WST
WST
Q4 25
$32.0M
$132.1M
Q3 25
$16.9M
$140.0M
Q2 25
$25.3M
$131.8M
Q1 25
$19.5M
$89.8M
Q4 24
$33.7M
$130.1M
Q3 24
$24.5M
$136.0M
Q2 24
$25.4M
$111.3M
Q1 24
$22.4M
$115.3M
Gross Margin
WMK
WMK
WST
WST
Q4 25
25.3%
37.8%
Q3 25
24.7%
36.6%
Q2 25
25.2%
35.7%
Q1 25
24.8%
33.2%
Q4 24
25.4%
36.5%
Q3 24
24.6%
35.4%
Q2 24
25.1%
32.8%
Q1 24
24.9%
33.1%
Operating Margin
WMK
WMK
WST
WST
Q4 25
3.2%
19.5%
Q3 25
1.7%
20.8%
Q2 25
2.5%
20.1%
Q1 25
1.8%
15.3%
Q4 24
3.3%
21.3%
Q3 24
2.3%
21.6%
Q2 24
2.6%
18.0%
Q1 24
2.2%
17.7%
Net Margin
WMK
WMK
WST
WST
Q4 25
2.5%
16.4%
Q3 25
1.4%
17.4%
Q2 25
2.1%
17.2%
Q1 25
1.6%
12.9%
Q4 24
2.7%
17.4%
Q3 24
2.1%
18.2%
Q2 24
2.1%
15.9%
Q1 24
1.9%
16.6%
EPS (diluted)
WMK
WMK
WST
WST
Q4 25
$1.27
$1.82
Q3 25
$0.69
$1.92
Q2 25
$0.96
$1.82
Q1 25
$0.73
$1.23
Q4 24
$1.25
$1.78
Q3 24
$0.91
$1.85
Q2 24
$0.95
$1.51
Q1 24
$0.83
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
WMK
WMK
WST
WST
Cash + ST InvestmentsLiquidity on hand
$214.2M
$791.3M
Total DebtLower is stronger
$202.8M
Stockholders' EquityBook value
$1.4B
$3.2B
Total Assets
$2.0B
$4.3B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
WMK
WMK
WST
WST
Q4 25
$214.2M
$791.3M
Q3 25
$177.6M
$628.5M
Q2 25
$188.8M
$509.7M
Q1 25
$337.9M
$404.2M
Q4 24
$382.3M
$484.6M
Q3 24
$381.2M
$490.9M
Q2 24
$398.7M
$446.2M
Q1 24
$397.5M
$601.8M
Total Debt
WMK
WMK
WST
WST
Q4 25
$202.8M
Q3 25
$202.7M
Q2 25
$202.6M
Q1 25
$202.6M
Q4 24
$202.6M
Q3 24
$202.6M
Q2 24
$205.8M
Q1 24
$206.2M
Stockholders' Equity
WMK
WMK
WST
WST
Q4 25
$1.4B
$3.2B
Q3 25
$1.3B
$3.1B
Q2 25
$1.3B
$2.9B
Q1 25
$1.4B
$2.7B
Q4 24
$1.4B
$2.7B
Q3 24
$1.4B
$2.8B
Q2 24
$1.4B
$2.6B
Q1 24
$1.4B
$2.7B
Total Assets
WMK
WMK
WST
WST
Q4 25
$2.0B
$4.3B
Q3 25
$2.0B
$4.1B
Q2 25
$1.9B
$4.0B
Q1 25
$2.1B
$3.6B
Q4 24
$2.1B
$3.6B
Q3 24
$2.1B
$3.7B
Q2 24
$2.1B
$3.5B
Q1 24
$2.0B
$3.6B
Debt / Equity
WMK
WMK
WST
WST
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.08×
Q4 24
0.08×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
WMK
WMK
WST
WST
Operating Cash FlowLast quarter
$86.6M
$251.1M
Free Cash FlowOCF − Capex
$36.4M
$175.0M
FCF MarginFCF / Revenue
2.8%
21.7%
Capex IntensityCapex / Revenue
3.9%
9.5%
Cash ConversionOCF / Net Profit
2.71×
1.90×
TTM Free Cash FlowTrailing 4 quarters
$4.8M
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
WMK
WMK
WST
WST
Q4 25
$86.6M
$251.1M
Q3 25
$59.2M
$197.2M
Q2 25
$56.6M
$177.1M
Q1 25
$4.9M
$129.4M
Q4 24
$87.1M
$190.1M
Q3 24
$25.8M
$180.1M
Q2 24
$40.3M
$165.0M
Q1 24
$34.2M
$118.2M
Free Cash Flow
WMK
WMK
WST
WST
Q4 25
$36.4M
$175.0M
Q3 25
$-4.7M
$133.9M
Q2 25
$1.4M
$101.9M
Q1 25
$-28.3M
$58.1M
Q4 24
$33.7M
$85.2M
Q3 24
$-16.5M
$98.8M
Q2 24
$10.2M
$64.8M
Q1 24
$-1.3M
$27.6M
FCF Margin
WMK
WMK
WST
WST
Q4 25
2.8%
21.7%
Q3 25
-0.4%
16.6%
Q2 25
0.1%
13.3%
Q1 25
-2.4%
8.3%
Q4 24
2.7%
11.4%
Q3 24
-1.4%
13.2%
Q2 24
0.9%
9.2%
Q1 24
-0.1%
4.0%
Capex Intensity
WMK
WMK
WST
WST
Q4 25
3.9%
9.5%
Q3 25
5.1%
7.9%
Q2 25
4.5%
9.8%
Q1 25
2.8%
10.2%
Q4 24
4.3%
14.0%
Q3 24
3.6%
10.9%
Q2 24
2.5%
14.3%
Q1 24
3.0%
13.0%
Cash Conversion
WMK
WMK
WST
WST
Q4 25
2.71×
1.90×
Q3 25
3.50×
1.41×
Q2 25
2.24×
1.34×
Q1 25
0.25×
1.44×
Q4 24
2.59×
1.46×
Q3 24
1.05×
1.32×
Q2 24
1.58×
1.48×
Q1 24
1.53×
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

WMK
WMK

Grocery$1.0B80%
Pharmacy$186.7M14%
Fuel Product$66.5M5%
Services$5.9M0%
Manufacturing$2.2M0%

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons